Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain zapping after symptom trigger shows promise for tough OCD

NCT ID NCT07429500

Symptom relief Sponsor: Centre Hospitalier Henri Laborit Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether provoking OCD symptoms right before a gentle brain stimulation technique (tDCS) can boost its effects. About 178 adults with treatment-resistant OCD will receive either tDCS alone or tDCS preceded by symptom provocation. The goal is to see if the combined approach leads to greater symptom reduction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 178 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Obsessive-Compulsive Disorder (OCD) according to DSM-5, with a duration ≥ 2 years. * Good insight, defined as a BABS score ≤ 18. * Chronic OCD, with either a Y-BOCS total score \> 20 or a subscale score \> 15. * Treatment-resistant OCD, defined as: * failure of ≥ two adequate trials of SSRIs, or * failure of one SSRI plus augmentation with an atypical antipsychotic, * and/or insufficient response after ≥ one year of cognitive-behavioural therapy. * Stable pharmacological treatment (fixed antidepressant dose) for at least 12 weeks prior to inclusion, with no significant improvement during this period. * Age 18 to 70 years. * Ability to provide informed written consent. * Affiliation with the French social security system. Exclusion Criteria: * Women of childbearing potential without effective contraception, or those unwilling to maintain abstinence or contraception. * Pregnancy or breastfeeding. * Compulsory psychiatric hospitalisation. * Legal guardianship or curatorship. * Current DSM-5 Axis I disorder other than OCD (schizophrenia spectrum, bipolar disorder, substance use). * Current major depressive episode (MADRS \> 21). * Suicide risk (MADRS item 10 \> 3). * Dermatological lesions at electrode placement sites. * History of traumatic brain injury. * Presence of intracranial metal, pacemaker, or epilepsy. * Emergency situations or inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obsessive - compulsive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obsessive-compulsive disorder obsessive-compulsive personality disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obsessive - compulsive disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Camille Claudel

    Angoulême, 16000, France

  • CH Esquirol

    Limoges, France

  • CH Guillaume Régnier

    Rennes, 35000, France

  • CHNDS

    Thouars, 79100, France

  • CHU de Nantes

    Nantes, 44000, France

  • Unité de Recherche Clinique, Centre Hospitalier Henri Laborit

    Poitiers, 86000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.